Vowst denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for vowst are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Limits VOWST Quantities — and Why You Can Appeal

VOWST (fecal microbiota spores, live) is an FDA-approved microbiome therapy for preventing recurrent Clostridioides difficile infection (rCDI). Blue Cross Blue Shield plans routinely impose quantity limits on VOWST, typically restricting the number of treatment courses dispensed within a defined period. These limits are designed to align with a "one-course" or "single-episode" framing — but many patients have genuine clinical reasons that a prescriber, working from the FDA-approved prescribing label, would determine warrant the dispensed amount. When the quantity your prescriber ordered exceeds the plan's limit, BCBS will issue a quantity-limit denial.

## Why This Denial Is Appealable

Quantity limits must be clinically justified. Under the Affordable Care Act (ACA §2719) and applicable state insurance law, you have the right to an internal appeal followed by an independent external review. If your plan is employer-sponsored and governed by ERISA, ERISA §503 guarantees a full-and-fair review. The external review window is typically available within approximately four months of a final internal denial, and an expedited external review (decision often within 72 hours) is available when your health is at risk from delay.

BCBS is required to apply its quantity-limit criteria consistently and to provide the clinical basis for the limit in writing. If your prescriber's order is grounded in the FDA-approved labeling, the denial is contestable.

## What to Gather

• Diagnosis confirmation: Chart documentation establishing recurrent CDI, including dates of each episode and the treating clinician's records.
• Prior-treatment history: Dates, agents used, duration, and documented outcomes of all prior CDI treatments, including antibiotic courses.
• Clinical severity documentation: Chart notes and lab findings showing the severity and frequency of recurrences.
• Prescriber medical-necessity letter: A letter from the ordering provider explaining why the prescribed quantity is consistent with the FDA-approved labeling and necessary for your specific clinical situation.
• The FDA prescribing label: Obtain and attach the current full prescribing information for VOWST directly from the FDA label, which defines the approved dosing regimen.

## Criteria-Mapping Structure

When you write your appeal, pull the exact quantity limit criteria from BCBS's published medical policy for VOWST (request it in writing if you do not have it). Then, for each criterion, write one sentence citing the exact chart fact that satisfies it. Example format:

> BCBS criterion: [paste verbatim from policy] > Chart evidence: [exact date, note, or lab result from your record]

This structure forces the reviewer to address your evidence point-by-point rather than issuing a form denial. Attach the FDA label, the prescriber letter, and all supporting chart records as exhibits.

## Timeline

File your internal appeal immediately upon receiving the denial. Most BCBS plans allow 180 days to file; confirm the exact deadline in your denial letter. Request an expedited review in writing if your condition is urgent. If the internal appeal is denied, file for external review without delay to preserve your rights within the external-review window.